Growth factor

• US 5,077,276 A
• Filed: 02/12/1990
• Issued: 12/31/1991
• Est. Priority Date: 08/22/1985
• Status: Expired due to Term

• Current Assignee: Novozymes Biopharma DK A/S (Novozymes)
• Original Assignee: Gropep, Ltd.
• Inventors: Ballard, Francis J., Bagley, Christopher J., Francis, Geoffrey L., Wallace, John C.
• Primary Examiner(s): Doll, John
• Assistant Examiner(s): Chan, Christina
• Application Number:
  US07/479,183
• Time in Patent Office: 687 Days
• Field of Search: 530/303, 530/324, 530/305, 530/333, 530/344, 514/3, 514/12, 514/21
• US Class Current: 514/8.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/65 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Abstract

A peptide analogue of mammalian insulin-like growth factor-1 wherein from 1 to 5 amino acid residues are absent from the N-terminal.

Claims

1. A peptide analogue of bovine or human insulin-like growth factor-1 having the structure:

X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala

wherein X is the N-terminal structure;

Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.

2. A peptide analogue according to claim 1 in a biologically pure form.

3. A pharmaceutical or vertinary composition for the treatment of protein accumulation deficiencies or protein loss in mammals including:

(a) an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure;

X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala

wherein X is the N-terminal structure;

Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly; and

(b) a pharmaceutically or venterinarilly acceptable diluent, carrier or excipient therefor.

4. A composition according to claim 3 wherein the peptide analogue is present in amounts of from approximately 0.02 to 2000 milligrams.

5. A method for the treatment of protein accumulation deficiencies in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure:

X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala

wherein X is the N-terminal structure;

Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.

6. A method according to claim 5 wherein the protein accumulation deficiencies to be treated are those which are associated with cancer, cystic fibrosis, Duchenne muscular dystrophy, Becker dystrophy, autosomal recessive dystrophy, polymyositis, or other myophathies.

7. A method according to claim 5 wherein the peptide analogue is administered at a dose rate of approximately 1 to 1000 microgram/kg bodyweight/day.

8. A method for the treatment of protein loss in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure:

X-try-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala

wherein X is the N-terminal structure;

Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.

9. A method according to claim 8 wherein the protein loss is related to burns, skeletal trauma or infection.

10. A method according to claim 8 wherein the peptide analogue is administered at a dose rate of approximately 1 to 1000 microgram/kg bodyweight/day.